Mapi Pharma
Pharmaceutical ManufacturingCentral District, Israel51-200 Employees
Mapi Pharma is a mid-sized Israeli pharmaceutical company focused on developing and manufacturing long-acting depot injectable therapies. Its lead product, GA Depot, is a depot formulation of glatiramer acetate for relapsing forms of multiple sclerosis and is in the late stage of Phase III development; it is the first in a planned series of depot injections. The company also markets generic products and pursues lifecycle management therapies that involve complex active ingredients and formulations, with a Phase II program for PPMS and a pipeline that includes GLP-1 agents for diabetes and neurodegenerative diseases. Mapi is headquartered in Ness Ziona in the Central District of Israel, with R&D facilities in Israel and manufacturing sites including an API plant in Neot-Hovav Eco Industrial Park and a Jerusalem Fill & Finish facility for injectable finished dosage forms. In 2026, the company indicated expansion of its depot program to include long-acting formulations for the antipsychotic Cariprazine and GLP-1 agents like Semaglutide and Tirzepatide, alongside a generic AB-rated version of Naltrexone.
1-888-653-2347 
support@leadiq.com 
